Skip to main content

Media Coverage

This section contains a selection of reportings about SphingoTec in the news.

 

14. April 2022
A multi-center study led by the University Hospital Hamburg-Eppendorf (UKE) is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.
Read more
12. April 2022
Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine for the treatment of COVID-19.
Read more
19. October 2021
Serial entrepreneur and industry expert Dr. Andreas Bergmann explains his diagnostic strategy in an interview.
Read more
12. August 2021
Learn more about three major sepsis pathways and how to improve patients outcomes and clinical decisions in the Technology Networks Article by Dr. Karolina Szczesna.
Read more
31. May 2021
In a Private Wealth cover story, Dr. Andreas Bergmann shares his vision and progress towards developing new diagnostics and drugs for diseases that are recognized as global health burdens, such as sepsis.
Read more
19. May 2021
Innovations made in Germany: We are excited to be featured in this Deutsche Welle coverage as healthcare innovators, alongside Biontech and other pioneers of the complex biotech scenery.
Read more
29. March 2021
New tool for critical care: read about the clinical relevance of DPP3 and its potential role in the management of septic patients.
Read more
23. February 2021
A BioWorld article looks at personalized sepsis management: SphingoTec's biomarkers could help to determine the best treatment for critically ill patients. Read the full article for more details.
Read more
18. December 2020
Acute Kidney Injury is affecting 1 in 3 Intensive Care Unit (ICU) patients and the current standard of care diagnostics has considerable sensitivity and specificity limitations, there is an urgent need to implement new biomarkers to assist a better management of AKI.
Read more
16. December 2020
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI). Read more in the following article.
Read more
10. December 2020
Die Uniklinik RWTH Aachen und die SphingoTec GmbH („SphingoTec“) gaben heute bekannt, dass sie ihre Zusammenarbeit mit der Implementierung der neuen Biomarker in der klinischen Routine weiter ausgebaut haben.
Read more
16. September 2020
penKid is an established biomarker for detecting AKI in adults. The current study shows that reference values for penKid in children are much higher than in adults. Read more here.
Read more
23. July 2020
Diagnostics company SphingoTec GmbH announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).
Read more
23. July 2020
SphingoTec launched IB10 Sphingotest bio-ADM, a CE IVD-marked point-of-care test to quantitatively determine blood levels of bioactive adrenomedullin.
Read more
22. July 2020
Diagnostics company SphingoTec GmbH ("SphingoTec") today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM®).
Read more
18. June 2020
Experts representing European medical centers agreed that novel biomarkers are required for triaging and monitoring of these patients to optimally make use of the available medical resources and improve outcomes.
Read more
15. May 2020
High blood levels of Dipeptidyl Peptidase 3 (DPP3) indicate the upcoming multiple organ failure and death in burn patients, as announced by the Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH.
Read more
15. May 2020
The publication of new data shows that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risks in burn patients.
Read more
14. May 2020
High blood concentrations of the biomarker DPP3, previously described as an indicator of massive cell death and inflammation, has been shown to be associated with organ failure fatal outcomes in patients with severe burns.
Read more
18. March 2020
Sepsis is a potentially life-threatening condition caused by the body's response to an infection. The body normally releases chemicals into the bloodstream to fight infection. Read more here.
Read more
02. March 2020
Proenkephalin (PENK) is a novel candidate biomarker for kidney function that is filtrated in the glomerulus, shown to represent steady-state GFR in patients with different severities of renal insufficiency and is reliably predictive for acute kidney injury in patients with severe burns.
Read more
24. February 2020
Bioactive Adrenomedullin is a biomarker for endothelial dysfunction and allows the prediction of septic shock as elevated blood levels of bio-ADM® predict blood pressure break down and blood vessel leakage resulting in edema
Read more
22. January 2020
Diagnostics company SphingoTec GmbH have announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin (penKid®), the biomarker that allows real-time assessment of kidney function with a simple blood test. Read the full article here.
Read more
14. January 2020
Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland. Read more in the press release.
Read more
28. August 2000
SphingoTec's kidney function biomarker penKid® was found to accurately detect acute kidney injury (AKI) in infants.
Read more